Indoximod

N/A

Report date: 2024/12/28 20:00:07
NME

Base Information

Drug NameIndoximod
Drug Alias Name1-methyltryptophan英多莫德d-1-methyltryptophan吲哚莫德1-methyl-D-tryptophan +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIndoleamine 2,3-dioxygenase inhibitors
TargetsIndoleamine 2,3-dioxygenase
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursProstatic Neoplasms +[17] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPoland
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNewlink Genetics Co
China Registration ClassN/A

Develop Information

Active CompaniesAugusta UniversityEmory University
Inactive CompaniesNewlink Genetics CoMasonic Cancer Center, University Of MinnesotaNational Cancer Institute
Active IndicationsBrain NeoplasmsMedulloblastomaEpendymoma +[5] 
Inactive IndicationsMetastatic breast cancerSolid tumoursProstatic Neoplasms +[12] 

Other Information

ATC CodeN/A
Related LinksKEGG